Mary Kathleen Flynn

Thoma Bravo announces debut deal of the year; Matt Leeds featured in new Dealmakers to Watch series

Thoma Bravo has agreed to take Everbridge private in $1.5 billion deal.

Blackstone hires; Webster reportedly preps CRO for sale; PFCFO’s New York Forum kicks off

Webster preps to put CenExel Clinical Research on the block.

TA Associates bets on software for community banks; plus an exclusive look at Paul Hastings’ IPO report

TA Associates invests in Computer Services Inc.

MidOcean, Kroger team up; plus a Deep Dive into a clean energy deal from Ara Partners

MidOcean inks partnership with supermarket chain Kroger.

EY increasingly optimistic about pharma M&A; Pelican Energy Partners acquires CTI

Pelican Energy Partners snaps up Container Technologies Industries.

EY's Arda Ural: Big pharma is driving a rebound in biopharma and medtech M&A

The most sought-after targets are small- to mid-sized companies focused on high-growth therapeutic areas, such as oncology, cardiometabolic, immunology, central nervous system and rare diseases.

The beauty of private equity; plus deals from Arlington Capital Partners and AUA

AUA Private Equity acquires a popcorn maker.

Asante Capital's Fraser van Rensburg: 'The beauty of private equity is the luxury of having time'

'PE has outperformed any other institutional asset class since its inception in the 1970s, as measured over 3 years, 5 years, 10 years, 20 years, or by any metric.'

Hamilton Lane's Hartley Rogers: Private equity will separate into winners and losers

'This next year or two will be interesting as there could well be an industry shakeout for the first time since the dot-com bubble exploded in 2000.'

Cambridge Associates' Andrea Auerbach: Rate cuts in 2024 may break the transaction logjam and spur activity

'Much like covid variants, 2023’s challenges will evolve and expand as we head into 2024, and some might even abate.'